Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$33.53
-0.10-0.30%
À la fermeture: -
$33.53
0.000.00%
Après les heures de négociation: Oct 24, 4:00 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Ultragenyx Pharmaceutical Inc a un objectif de cours consensus de $89.58, basé sur les évaluations des 24 analystes. Le plus élevé est de $140 attribué par Piper Sandler le janvier 13, 2025, et le plus bas est de $34 attribué par Wedbush le juillet 14, 2025. Les 3 dernières évaluations d'analystes ont été publiées par HC Wainwright & Co., Cantor Fitzgerald et Canaccord Genuity le septembre 9, 2025, septembre 5, 2025 et août 8, 2025. Avec un objectif de cours moyen de $104.33 entre HC Wainwright & Co., Cantor Fitzgerald et Canaccord Genuity, il y a une variation implicite de 211.16% upside pour Ultragenyx Pharmaceutical Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
HC Wainwright & Co.
Cantor Fitzgerald
Canaccord Genuity
Wedbush
Morgan Stanley
1calculé à partir des notes des analystes
Notes d'analystes pour Ultragenyx Pharmaceutical
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
09/09/2025 | 138.59% | HC Wainwright & Co. | $80 → $80 | Reiterates | Buy → Buy | |||
09/05/2025 | 213.15% | Cantor Fitzgerald | $105 → $105 | Reiterates | Overweight → Overweight | |||
08/08/2025 | 281.75% | Canaccord Genuity | $136 → $128 | Maintains | Buy | |||
08/06/2025 | 213.15% | Cantor Fitzgerald | $112 → $105 | Maintains | Overweight | |||
07/28/2025 | 138.59% | HC Wainwright & Co. | → $80 | Assumes | → Buy | |||
07/14/2025 | 1.4% | Wedbush | $35 → $34 | Maintains | Neutral | |||
07/14/2025 | 64.03% | Morgan Stanley | $65 → $55 | Maintains | Overweight | |||
07/10/2025 | 93.86% | Wells Fargo | $88 → $65 | Maintains | Overweight | |||
06/20/2025 | 90.87% | Guggenheim | $64 → $64 | Reiterates | Buy → Buy | |||
05/28/2025 | 93.86% | William Blair | → $65 | Initiates | → Outperform | |||
05/09/2025 | 93.86% | Morgan Stanley | $64 → $65 | Maintains | Overweight | |||
03/27/2025 | 248.94% | JP Morgan | $104 → $117 | Maintains | Overweight | |||
03/17/2025 | 242.98% | Piper Sandler | $140 → $115 | Maintains | Overweight | |||
02/26/2025 | 251.92% | Cantor Fitzgerald | $118 → $118 | Reiterates | Overweight → Overweight | |||
02/18/2025 | 183.33% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
02/18/2025 | 305.61% | Canaccord Genuity | $121 → $136 | Maintains | Buy | |||
02/14/2025 | 183.33% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
01/22/2025 | 251.92% | Cantor Fitzgerald | $118 → $118 | Reiterates | Overweight → Overweight | |||
01/13/2025 | 317.54% | Piper Sandler | $135 → $140 | Maintains | Overweight | |||
01/13/2025 | 43.16% | Wedbush | $46 → $48 | Reiterates | Neutral → Neutral | |||
12/24/2024 | 183.33% | HC Wainwright & Co. | $95 → $95 | Reiterates | Buy → Buy | |||
12/20/2024 | 162.45% | Wells Fargo | $75 → $88 | Maintains | Overweight | |||
11/21/2024 | 204.21% | JP Morgan | $105 → $102 | Maintains | Overweight | |||
11/12/2024 | 260.87% | Canaccord Genuity | $121 → $121 | Maintains | Buy | |||
11/06/2024 | 260.87% | Canaccord Genuity | $109 → $121 | Maintains | Buy | |||
11/06/2024 | 129.65% | RBC Capital | $77 → $77 | Reiterates | Outperform → Outperform | |||
11/06/2024 | 245.96% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
11/06/2024 | 183.33% | HC Wainwright & Co. | $82 → $95 | Maintains | Buy | |||
10/22/2024 | 245.96% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
10/21/2024 | 117.72% | TD Cowen | $61 → $73 | Maintains | Buy | |||
10/01/2024 | 245.96% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
09/26/2024 | 129.65% | RBC Capital | $77 → $77 | Reiterates | Outperform → Outperform | |||
09/20/2024 | 245.96% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 245.96% | Cantor Fitzgerald | $116 → $116 | Reiterates | Overweight → Overweight | |||
08/05/2024 | 141.57% | Barclays | $83 → $81 | Maintains | Overweight | |||
08/02/2024 | 123.68% | Wells Fargo | $72 → $75 | Maintains | Overweight | |||
08/02/2024 | 126.66% | Goldman Sachs | $67 → $76 | Maintains | Buy | |||
08/02/2024 | 245.96% | Cantor Fitzgerald | $115 → $116 | Maintains | Overweight | |||
08/02/2024 | 37.19% | Wedbush | $43 → $46 | Maintains | Neutral | |||
07/23/2024 | 231.05% | Canaccord Genuity | $111 → $111 | Maintains | Buy | |||
07/22/2024 | 242.98% | Cantor Fitzgerald | $115 → $115 | Reiterates | Overweight → Overweight | |||
07/18/2024 | 34.21% | Wedbush | $45 → $45 | Reiterates | Neutral → Neutral | |||
06/12/2024 | 242.98% | Cantor Fitzgerald | $115 → $115 | Reiterates | Overweight → Overweight | |||
06/06/2024 | 99.82% | Goldman Sachs | $56 → $67 | Upgrade | Neutral → Buy | |||
05/31/2024 | 43.16% | Wedbush | $47 → $48 | Maintains | Neutral | |||
05/31/2024 | 126.66% | B of A Securities | $83 → $76 | Maintains | Buy | |||
05/31/2024 | 231.05% | Canaccord Genuity | $109 → $111 | Maintains | Buy | |||
05/31/2024 | 242.98% | Cantor Fitzgerald | $107 → $115 | Maintains | Overweight | |||
05/31/2024 | 278.77% | Stifel | $124 → $127 | Maintains | Buy | |||
05/31/2024 | 114.73% | Baird | $68 → $72 | Maintains | Outperform | |||
05/06/2024 | 225.08% | Canaccord Genuity | $111 → $109 | Maintains | Buy | |||
05/03/2024 | 219.12% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
05/03/2024 | 40.17% | Wedbush | $48 → $47 | Maintains | Neutral | |||
04/24/2024 | 81.93% | TD Cowen | $59 → $61 | Maintains | Buy | |||
04/22/2024 | 129.65% | RBC Capital | → $77 | Initiates | → Outperform | |||
04/17/2024 | 43.16% | Wedbush | $48 → $48 | Reiterates | Neutral → Neutral | |||
04/16/2024 | 43.16% | Wedbush | $48 → $48 | Reiterates | Neutral → Neutral | |||
04/05/2024 | 219.12% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
03/18/2024 | 174.38% | JP Morgan | $88 → $92 | Maintains | Overweight | |||
02/27/2024 | 219.12% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
02/27/2024 | 162.45% | JP Morgan | $84 → $88 | Maintains | Overweight | |||
02/21/2024 | 231.05% | Canaccord Genuity | $110 → $111 | Maintains | Buy | |||
02/16/2024 | 43.16% | Wedbush | $47 → $48 | Maintains | Neutral | |||
02/15/2024 | 239.99% | Cantor Fitzgerald | $114 → $114 | Reiterates | Overweight → Overweight | |||
01/30/2024 | 102.8% | Baird | $57 → $68 | Maintains | Outperform | |||
01/19/2024 | 239.99% | Cantor Fitzgerald | $114 → $114 | Reiterates | Overweight → Overweight | |||
12/08/2023 | 114.73% | Wells Fargo | → $72 | Initiates | → Overweight | |||
11/03/2023 | 150.52% | Morgan Stanley | $90 → $84 | Maintains | Overweight | |||
10/25/2023 | 287.71% | Piper Sandler | $135 → $130 | Maintains | Overweight | |||
10/10/2023 | 168.42% | Morgan Stanley | $95 → $90 | Maintains | Overweight | |||
09/25/2023 | 239.99% | Cantor Fitzgerald | → $114 | Reiterates | Overweight → Overweight | |||
08/04/2023 | 183.33% | Morgan Stanley | $95 → $95 | Reiterates | Overweight → Overweight | |||
08/01/2023 | 144.56% | HC Wainwright & Co. | → $82 | Reiterates | Buy → Buy | |||
06/14/2023 | 186.31% | Credit Suisse | → $96 | Assumes | → Outperform | |||
06/07/2023 | 296.66% | Citigroup | $130 → $133 | Maintains | Buy | |||
06/06/2023 | 138.59% | Evercore ISI Group | $60 → $80 | Upgrade | In-Line → Outperform | |||
06/06/2023 | 52.1% | Wedbush | $48 → $51 | Maintains | Neutral | |||
05/08/2023 | 43.16% | Wedbush | $47 → $48 | Maintains | Neutral | |||
05/05/2023 | 287.71% | Citigroup | $130 → $130 | Maintains | Buy | |||
05/05/2023 | 186.31% | Credit Suisse | → $96 | Reiterates | → Outperform | |||
04/26/2023 | 239.99% | Cantor Fitzgerald | → $114 | Initiates | → Overweight | |||
03/18/2023 | 287.71% | Citigroup | $135 → $130 | Maintains | Buy | |||
02/17/2023 | 186.31% | Credit Suisse | → $96 | Reiterates | → Outperform | |||
02/17/2023 | 70% | Baird | $50 → $57 | Maintains | Outperform | |||
02/03/2023 | 183.33% | Morgan Stanley | $100 → $95 | Maintains | Overweight | |||
01/18/2023 | 168.42% | Canaccord Genuity | → $90 | Assumes | → Buy | |||
01/09/2023 | 302.62% | Citigroup | $138 → $135 | Maintains | Buy | |||
12/30/2022 | 144.56% | HC Wainwright & Co. | → $82 | Assumes | → Buy | |||
11/04/2022 | 64.03% | Goldman Sachs | $74 → $55 | Maintains | Neutral | |||
11/03/2022 | 311.57% | Citigroup | $142 → $138 | Maintains | Buy | |||
11/03/2022 | 198.24% | Morgan Stanley | $109 → $100 | Maintains | Overweight | |||
11/03/2022 | 222.1% | SVB Leerink | $115 → $108 | Maintains | Outperform | |||
11/03/2022 | 186.31% | Credit Suisse | $105 → $96 | Maintains | Outperform | |||
11/03/2022 | 49.12% | Baird | $63 → $50 | Upgrade | Neutral → Outperform |
FAQ
Quel est le cours indicatif de l'action Ultragenyx Pharmaceutical (RARE) ?
Le dernier objectif de prix pour Ultragenyx Pharmaceutical (NASDAQ:RARE) a été rapporté par HC Wainwright & Co. le septembre 9, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $80.00 s'attendant à ce que RARE se rise dans les 12 prochains mois (un possible changement de 138.59% upside). 28 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Ultragenyx Pharmaceutical (RARE) ?
La dernière note d'analyste pour Ultragenyx Pharmaceutical (NASDAQ:RARE) a été fournie par HC Wainwright & Co., et Ultragenyx Pharmaceutical réitéré leur note buy.
Quand a eu lieu la dernière mise à niveau pour Ultragenyx Pharmaceutical (RARE) ?
La dernière amélioration pour Ultragenyx Pharmaceutical Inc a eu lieu le juin 6, 2024 lorsque Goldman Sachs a augmenté leur objectif de prix à $67. Goldman Sachs avait précédemment a neutral pour Ultragenyx Pharmaceutical Inc.
Quand a eu lieu la dernière dégradation pour Ultragenyx Pharmaceutical (RARE) ?
Il n'y a pas de dernière réduction pour Ultragenyx Pharmaceutical.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Ultragenyx Pharmaceutical (RARE) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Ultragenyx Pharmaceutical, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Ultragenyx Pharmaceutical a été déposée le septembre 9, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers septembre 9, 2026.
La note d'analyste pour Ultragenyx Pharmaceutical (RARE) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Ultragenyx Pharmaceutical (RARE) était un réitéré avec un objectif de prix de $80.00 à $80.00. Le prix actuel de Ultragenyx Pharmaceutical (RARE) est de $33.53, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.